Intas Pharmaceuticals / Accord BioPharma Acquires UDENYCA Franchise from Coherus BioSciences
August 6, 2025
Intas Pharmaceuticals, via its U.S. specialty division Accord BioPharma, completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences. The asset sale expands Accord/Intas' FDA-approved biosimilar portfolio—particularly in oncology supportive care—and brings key Coherus commercial and manufacturing personnel into Accord to support continuity and growth in the U.S. and international markets.
- Buyers
- Intas Pharmaceuticals, Accord BioPharma, Inc.
- Targets
- UDENYCA (pegfilgrastim-cbqv)
- Sellers
- Coherus BioSciences, Inc.
- Industry
- Pharmaceuticals
- Location
- North Carolina, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.